Schering-Plough Merck Reverse Merger Shareholder Class Action
Schering-Plough and Merck announced plans for a reverse merger to form one company. Under the terms of the reverse merger, Schering-Plough shareholders would be given $10.56 in cash and .5767 shares of Merck stock for each Schering-Plough share. Although these provisions appeared to provide a premium to Schering-Plough stock owners when the deal was announced, many believe that the deal has been grossly unfair to Schering-Plough stockholders. Merck will gain control of the merged companies from the reverse-merger causing Schering-Plough stockholders to object to the proposed reverse merger.
Contact Us
If you own Schering-Plough stock and you object to the Schering-Plough Merck reverse merger, and you would like to speak with an attorney about your rights, contact Seeger Weiss LLP. Our securities fraud team is investigating the Merck Schering-Plough reverse merger for a potential shareholder class action on behalf of Schering-Plough shareholders who feel they have not been offered a reasonable value for their investment. Please use the contact form or call 888-584-0411. Attorney consultations incur no obligation on your part. All initial consultations are free of charge and do not create an attorney-client relationship. Seeger Weiss LLP has office locations in New York, New Jersey, Pennsylvania and California and its attorneys are available to practice in courts throughout the country.
- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Accutane Side Effects
- Darvon and Darvocet
- DePuy Hip Recall
- Fosamax Femur Fractures
- Muscle Injury
- SSRI Birth Defects
- Topamax Birth Defects
- Transvaginal Surgical Mesh and Bladder Slings
- Tylenol Liver Damage
- Zocor/Simvastatin
